Diffuse Midline Glioma (DMG) is an aggressive brain tumor that primarily affects children. Unfortunately, this cancer is difficult to treat, and the impact of existing therapies, such as surgery, radiation, and chemotherapy, is limited. The prognosis for DMG is extremely poor, and new treatment options are urgently needed.
Here, we aim to explore Delta-24-RGD, a genetically modified virus designed to replicate in tumor cells, leading to tumor cell break down. This therapy is delivered through injections directly to the tumor site as part of a clinical trial. Through this proposal, we will investigate its effectiveness by looking for signs of treatment response in key areas: cerebrospinal fluid (CSF), blood, and tumor tissue. By identifying biomarkers, or measurable indicators, of how the tumor responds to treatment in these areas, we hope to create a set of tools that can guide personalized treatments for each patient.
We aim to develop a better understanding of how to monitor and measure tumor response, leading to more effective therapies tailored to individual patients. In partnership with Seattle Children’s Hospital, the University of California San Francisco, and the Pediatric Neuro-Oncology Consortium (PNOC), we bring together leading experts and cutting-edge technologies to conduct this research. By refining the use of Delta-24-RGD, we hope to make a significant impact on how pediatric DMG is treated, offering new hope to families facing this challenging diagnosis.
